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ABSTRACT 
 
Over the last two decades muscle (magnetic resonance) imaging has become an important 
complementary tool in the diagnosis and differential diagnosis of inherited neuromuscular 
disorders, particularly in conditions where the pattern of selective muscle involvement is 
often more predictive of the underlying genetic background than associated clinical and 
histopathological features. 
Following an overview of different imaging modalities, the present review will give a concise 
introduction to systematic image analysis and interpretation in genetic neuromuscular 
disorders. The pattern of selective muscle involvement will be presented in detail in 
conditions such as the congenital or myofibrillar myopathies where muscle imaging is 
particularly useful to inform the (differential) diagnosis, and in disorders such as Duchenne or 
fascioscapulohumeral muscular dystrophy where the diagnosis is usually made on clinical 
grounds but where detailed knowledge of disease progression on the muscle imaging level 
may inform better understanding of the natural history. Utilizing the group of the congenital 
myopathies as an example, selected case studies will illustrate how muscle MRI can be used 
to inform the diagnostic process in the clinico-pathological context. Future developments, in 
particular concerning the increasing use of whole body MRI protocols and novel quantitative 
fat assessments techniques potentially relevant as an outcome measure, will be briefly 
outlined.        
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INTRODUCTION 
 
The diagnostic approach to inherited neuromuscular disorders is a complex process with the 
ultimate aim of establishing an unequivocal genetic explanation for the patient presenting 
with muscle weakness to the neuromuscular clinic. A comprehensive personal and family 
history, detailed clinical assessment, CPK level determination and neurophysiological studies 
have traditionally provided the cornerstones of this process, and the context for the 
interpretation of histopathological features on muscle biopsy.  
Over the last two decades, muscle imaging has become an important modality in 
neuromuscular diagnostics, based on the observation that different genetic defects do not 
affect all muscles equally and that distinct patterns of selective muscle involvement may thus 
point to a specific genetic background. Muscle imaging has become particularly relevant in 
neuromuscular disorders such as the congenital myopathies or the limb girdle muscular 
dystrophies where the same histopathological feature can be caused by a wide range of 
different mutations, or in heterogeneous syndromes such as the rigid spine syndrome (RSS) 
where identical clinical features do not offer any immediate clues as to the underlying genetic 
defect. Muscle imaging is less important as a diagnostic tool in conditions such as Duchenne 
muscular dystrophy, myotonic dystrophy or FSHD where the diagnosis can usually be readily 
made on clinical grounds, but is increasingly applied also in these conditions to monitor fatty 
muscle replacement more objectively through utilization of new MRI techniques. Although 
due to recent rapid advances genetic testing is performed increasingly early in the diagnostic 
process, muscle imaging is thus likely to retain its current role also in future, if only to 
ascertain the relevance of different genetic variants identified on massive parallel sequencing, 
or to monitor disease progression.            
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The following review will summarize the role of muscle imaging in the approach to 
neuromuscular disorders, focussing on inherited and myopathic conditions. The review will 
not cover acquired (in particular inflammatory) and neurogenic conditions, areas where 
muscle imaging does play a definite role but for which the reader is referred to other topical 
specialist reviews [1, 2]. Different imaging modalities will be summarized, a structured 
approach to muscle imaging analysis will be outlined and typical patterns of selective muscle 
involvement in common inherited neuromuscular disorders will be presented. Concise case 
studies utilizing the congenital myopathies as an example will illustrate how muscle imaging 
can be put into clinical practice, to aid interpretation of histopathological features or even 
substitute for a muscle biopsy where this cannot be performed. Potential and challenges for 
the future will be summarized in a concluding paragraph.   
 
IMAGING MODALITIES IN INHERITED MYOPATHIES 
 
Selective muscle involvement in inherited myopathies was originally demonstrated on early 
ultrasound, CT and MRI studies in the 1980s and 1990s. Although there are obvious 
associations between histopathological features on muscle biopsy and findings with different 
imaging modalities (Figure 1), there is clearly a lack of more comprehensive comparative 
studies, for example systematically correlating findings on muscle ultrasound and muscle MR 
imaging. Considering that atrophy and replacement of muscle tissue with fat and connective 
tissue are also features of the normal aging process, distinguishing the latter from genuinely 
myopathic changes may pose a considerable challenge, particularly in older patients, 
whatever imaging modality applied.  
Muscle ultrasound (US) was one of the first imaging modalities applied in the investigation 
of neuromuscular disorders. On muscle US imaging  (for review, [3-5]), normal muscle tissue 
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has low echogenicity and appears therefore dark, whereas in myopathies (and also in aging 
muscle and/or obese individuals), echogenicity is high and the appearance of the muscle 
brightens, due to fatty and/or connective tissue increases often associated with reduced 
echogenicity of underlying bone structures. Muscle contraction has the contrary effect and 
makes muscle appear darker, an observation that has to be taken into account with image 
interpretation. Even normal muscle never appears completely black on muscle US, due to the 
presence of physiological internal connective tissue structures such as the fascia that give rise 
to a speckled appearance on transverse sections and can be clearly visualized on longitudinal 
sections. Although the echogenicity increases in myopathic conditions appear more diffuse 
compared to the often “moth-eaten” appearance of primary neurogenic disorders, distinction 
can be challenging in individual patients. Main advantages of muscle ultrasound are its ready 
bedside availability (particularly in children) and its unique potential to capture real life 
pathognomic events such as fasciculation and fibrillations, but its use is limited by its inferior 
visualization of deeper muscle tissues compared to other imaging techniques, in particular 
muscle MRI.    
Muscle computer tomography (CT) (for review, [4, 5]) was widely applied in early imaging 
studies of neuromuscular disorders but has now been largely replaced by other imaging 
modalities except in cases where muscle MRI may be contraindicated (for example, a patient 
wearing a pacemaker), mainly reflecting the associated substantial radiation exposure and 
relatively low sensitivity. Muscle tissue replaced by fat appears more hypodense than normal 
muscle tissue on CT, but the technique is inferior compared to muscle MRI in detecting more 
subtle myopathic, inflammatory and/or edematous changes.  
The potential of muscle magnetic resonance imaging (MRI) to image healthy and diseased 
skeletal muscle with an unprecedented level of contrast and clarity has been recognized since 
the late 1980s [6]. Whilst initially mainly used for the diagnosis and monitoring of 
Muscle imaging and myopathology 
6 
 
inflammatory myopathies [1], muscle MRI (for review, [4, 5]) is now the method of choice 
for (diagnostic) muscle imaging of genetic neuromuscular disorders. Axial T1-weighted 
(turbo/fast) and T2-weighted (turbo/fast) spin echo sequences with or without fat suppression 
(for example, STIR) are the most frequently used imaging sequences and mirror specific 
histopathological features with different signal intensity changes (summarized in Table 1). 
Fatty and connective tissue replacement is reflected in increased signal intensity on T1-
weighted images, whereas in particular (fat suppressed) T2-weighted images can help to 
visualize edematous and inflammatory changes that may precede more definite changes in 
primary inflammatory myopathies or some of the muscular dystrophies. Muscle MRI lacks 
radiation and offers higher resolution compared to muscle CT, and allows for better 
visualization of deeper muscle layers compared to muscle US. Disadvantages are the 
relatively longer exposures required, in particular if whole body MRI is performed, resulting 
in the need for sedation or general anesthesia if young children are imaged. Whilst most of 
the early muscle MRI studies have focussed on the lower limbs, whole body MRIs 
increasingly performed more recently may provide additional useful information (including 
information on other organs such as the heart) whose value has to be balanced with the 
possible sedation requirement.     
Whilst most muscle MRI studies until recently had a strong diagnostic emphasis focussing on 
genotype-phenotype correlations on the radiological level, novel MRI techniques to quantify 
alterations of muscle fat more precisely and reproducibly are being put into practice with the 
ultimate aim to establish muscle MRI as a biomarker for natural history studies and therapy 
monitoring (for review, [7]). The most promising of these techniques is the 3-point Dixon 
technique [8, 9] suitable for quantification of the intramuscular fat content in an objective 
manner, thus allowing comparisons between different patients and the same patient at 
different time points in longitudinal studies. Other novel MRI techniques currently being 
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assessed for their practical value are magnetic resonance spectroscopy (MRS), suitable to 
measure water and fat concentrations (1H), energy metabolites (31P, glycogen 13C) that may 
be relevant for certain metabolic disorders [10] but also some of the muscular dystrophies 
[11-13], and intracellular sodium content (23Na) that may hold promise for the investigation 
of sodium channelopathies [14]. 
  
IMAGING INTERPRETATION IN INHERITED MYOPATHIES 
 
As with any other diagnostic modality, only rarely can a diagnosis be established based on 
muscle MRI or other imaging findings alone. Considering that the number of possible 
patterns of selective muscle involvement is finite and some muscle groups are more 
frequently affected than others throughout different myopathic conditions, additional 
information such as histopathological evidence of a dystrophic process or an elevated CK is 
invaluable in assigning a certain MRI pattern to a specific genetic background.       
Muscle MRI has to be based on sound knowledge of individual muscles and muscle groups, 
and there are several excellent publications summarizing muscle anatomy with a particular 
view to muscle MRI or CT interpretation (for example, [4]). Figure 2 illustrates muscle 
groups commonly analysed in the lower limb on the mid-thigh and the mid-calf level.     
The main general questions to be considered in the interpretation of muscle MR and CT 
images are i) if the muscle bulk is normal or reduced, ii) if there is any increase in signal 
intensity suggestive of increases in fat and connective tissue and/or abnormal water content, 
and, if yes, iii) if there is a pattern of selective involvement suggestive of a specific genetic 
background. Although the question of a non-physiological increase in signal intensity is 
usually easily answered in the Paediatric age group, the distinction may be less 
straightforward in older and obese patients where similar changes may occur without being 
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reflective of a primary myopathic process. Other considerations in the interpretation of 
muscle MRI are an assessment of the amount of subcutaneous fat (in particular looking for 
associated lipodystrophy), and of other organs such as the heart (in particular if a muscle 
condition with an associated cardiomyopathy is suspected) if whole body MRI is performed. 
Different visual rating scales have been designed to semi-quantify the amount of abnormally 
increased signal within a given muscle group based on how much of muscle tissue is being 
replaced by abnormal signal [15-17] and are summarized in [5].  
The more specific questions to be considered in the interpretation of muscle MR and CT 
imaging are iv) if the pattern of involvement is proximal or distal, and v) if the anterior and 
posterior compartments within the thighs and the legs are affected equally, or if there is 
anterior or posterior predominance. Considering that some muscles are more commonly 
spared (or affected) across different neuromuscular disorders (Table 2), involvement of a 
muscle that is usually spared (for example, of the rectus femoris in FSHD), or sparing of a 
muscle that is usually affected (for example, the quadriceps in DES-related MFM) might 
provide essential diagnostic clues. In addition, an assessment of the combined pattern of 
selective involvement at different levels (pelvis, thigh, calves) may strongly point at a 
specific genetic diagnosis, and is likely to be further informed through the more widespread 
use of whole body MR imaging. Lastly, additional unusual features (such as the “rimming” 
observed in COL6-related myopathies, or the marked lipodystrophy in laminopathies) may 
provide additional diagnostic clues.  
A systematic approach to the differential diagnosis of muscle imaging findings and very 
helpful diagnostic algorithms are summarized in [4, 5].          
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MUSCLE IMAGING IN SPECIFIC INHERITED NEUROMUSCULAR DISORDERS 
 
Muscle imaging has been applied through a wide range of inherited neuromuscular disorders 
but to variable extent and with different remit. In general, the diagnostic yield of muscle 
imaging is highest in stable or slowly progressive conditions with mild to moderate weakness 
in which selective patterns of muscle involvement can be discerned over prolonged periods of 
time (for example, some of the congenital myopathies), in contrast to very mild and/or 
episodic disorders without fixed weakness where muscle imaging may often be normal (for 
example, some metabolic myopathies or the periodic paralyses), or in profoundly severe 
disorders where muscle involvement may be so extensive that no selective involvement can 
be detected anymore. Muscle imaging is most useful in conditions with overlapping clinical 
and histopathological findings, where the clinico-pathological features do not immediately 
suggest a genetic diagnosis, and identification of a distinct pattern of selective muscle 
involvement may aid the choice of genetic testing (or variant interpretation where parallel 
sequencing of a large number of genes has already been performed). Muscle imaging is less 
important as a diagnostic tool in conditions such as Duchenne (DMD) and Becker muscular 
dystrophy (BMD), Fascio-Scapulo-Humeral Dystrophy (FSHD) or myotonic dystrophy (MD) 
that can be readily diagnosed on clinical and/or histopathological grounds, but may be useful 
also in these disorders if presentations are atypical, and, through application of novel MRI 
techniques, as a tool to objectively quantify intramuscular fat as an outcome measure. The 
following paragraph will outline characteristic imaging findings in selected inherited 
neuromuscular disorders (illustrated in Figure 3 and summarized in Table 2) (for a more 
detailed review, [4]).  
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Congenital myopathies 
The congenital myopathies – Central Core Disease (CCD), Multi-Minicore Disease (MmD), 
Centronuclear Myopathy (CNM), Nemaline Myopathy (NM) and Congenital Fibre Type 
Disproportion (CFTD) – are a genetically heterogeneous group of early-onset myopathies 
characterized by variable degrees of weakness, a normal or only mildly elevated CK, and 
defined by distinct features on muscle biopsy (for review, [18]). Considering that the same 
genetic background may cause highly variable histopathological presentations and that, vice 
versa, mutations in different genes may cause the same congenital myopathy, muscle MRI is 
often a better predictor of the causative gene than muscle biopsy (Case 1, Case 2). More than 
20 genes have been implicated in the various congenital myopathies to date. Mutations in the 
skeletal muscle ryanodine receptor (RYR1) gene are the most frequent genetic cause and have 
been associated with dominantly inherited CCD and subgroups of recessively inherited 
MmD, CNM and CFTD of which the first two (the “core myopathies” [19]) are the most 
common. Muscle imaging of the lower leg in RYR1-related core myopathies [16, 20], shows a 
distinct pattern characterized by prominent involvement of vasti, adductor magnus and 
sartorius in the thigh and of gastrocnemii and soleus in the leg, with relative sparing of the 
rectus femoris, adductor longus, gracilis and tibialis anterior (Table 2, Figure 3C, Figure 4A-
B, Case 1). Although the pattern of selective involvement is more diffuse in recessive 
compared to dominantly inherited forms, it is similar throughout all forms of RYR1-related 
myopathies and may be more consistent than associated histopathological features (Case 1) 
[21]. Recent whole body MRI studies in RYR1-related myopathies [22] (Figure 5) have 
demonstrated additional involvement of shoulder, neck, masticator and paravertebral 
muscles, the latter also a feature in the dominantly inherited RYR1-related malignant 
hyperthermia susceptibility trait, an allelic pharmacogenetic reaction to certain general 
anesthetics and muscle relaxants [23]. Muscle imaging may aid the differential diagnosis 
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between RYR1-related myopathies and other conditions with overlapping clinical and 
histopathological features, in particular those due to mutations in the SEPN1, the collagen 6 
(COL6) and DNM2 genes. Recessive mutations in SEPN1 are the second most common cause 
of core myopathies, in particular of the MmD variant [24]. Clinically, SEPN1-related MmD is 
characterized by early-onset scoliosis with spinal rigidity and respiratory impairment, but in 
contrast to recessive RYR1-related MmD, extraocular muscles are typically spared. Muscle 
MRI involvement in SEPN1-related myopathies (Table 2, Figure 3E) has been documented in 
several series [22, 25]: In addition to the striking axial involvement visible on whole body 
MRI, patients with SEPN1-related MmD often show marked wasting of the inner thigh 
(“bracket-like” appearance) [22, 25]. Within the thigh, the sartorius and semimembranosus 
muscles are most consistently involved; in cases where the lower leg is affected, 
gastrocnemius medialis and soleus tend to be more prominently affected (Table 2) [25]. Early 
and prominent sartorius involvement (Figure 3H) distinguishes SEPN1-related myopathies 
from other genetic causes of the rigid spine syndrome (RSS), in particular mutations in 
Lamin A/C (LMNA), the COL6 genes and acid maltase deficiency, as well as RYR1-related 
myopathies, where this feature usually occurs later in the disease course [26]. 
Centronuclear Myopathy (CNM) is due to X-linked recessive mutations in MTM1 encoding 
myotubularin [“X-linked myotubular myopathy (XLMTM)”] [27], autosomal-dominant 
mutations in DNM2 encoding dynamin2 [28] and the BIN1 gene encoding amphiphysin 2 
[29], autosomal-recessive mutations in BIN1 [30], RYR1 [31], and TTN encoding titin [32], 
and rarer genetic backgrounds [33-35]. Clinically, the associated muscle weakness is highly 
variable but, with the exception of TTN-related CNM, extraocular muscles are consistently 
involved. Muscle imaging studies in XLMTM have been mainly performed in the rare subset 
of more mildly affected males and manifesting female carriers, also often featuring “necklace 
fibres” in addition to diagnostic central nuclei on muscle biopsy [36]. In this group, the 
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reported pattern of selective muscle involvement (Table 2) shows some similarities to those 
reported in RYR1-related myopathies, in particular with regards to relative sparing of rectus 
femoris, and gracilis within an otherwise more diffusely affected thigh, which is of interest 
considering some shared pathogenic mechanisms between the two conditions [37]. 
Dominantly inherited DNM2-related CNM [28] is usually a much milder condition with the 
exception of rare cases associated with de novo inheritance [38]. Several studies have 
reported muscle MRI findings in DNM2-related CNM, suggesting some consistent and 
diagnostically useful features but also considerable variability, probably reflecting marked 
age differences in the cohorts studied [20, 39-41] (Table 2): In contrast to all other forms of 
CNM, distal weakness is prominent, and reflected in early and severe involvement of the 
tibialis anterior, the gastrocnemius (medialis) and the soleus. The thigh muscles are much 
later and less severely affected, with initial involvement of the posterior and later and milder 
involvement of the anterior compartment. Although not universally present, preferential 
involvement of rectus femoris and adductor longus [40] represents a mirror image of the 
pattern seen in RYR1-related myopathies and may support the distinction from RYR1-related 
CNM in individual cases. Marked axial and masticator involvement are additional supportive 
features on whole muscle MRI [22]. There are currently no larger series regarding imaging 
findings in TTN-related CNM and it remains to be seen if the pattern is similar to that seen in 
other TTN-related myopathies, demonstrating early hamstring involvement, in particular of 
the semitendinosus (Figure 3A).  
Nemaline myopathy (NM) is one of the more common congenital myopathies [42-44] and 
characterized by numerous nemaline rods on muscle biopsy. To date, 10 genes have been 
linked to this disorder, including ACTA1, NEB, TPM3, TPM2, CFL2, TNNT1, LMOD3, 
KBTBD13, KLHL40, and KLHL41 [45-47], the majority of those implicated in thin filament 
assembly and interaction. NM is associated with highly variable degrees of muscle weakness 
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[44, 46, 48, 49]. Bulbar and respiratory impairment are common in many genetic forms but 
extraocular muscle involvement is not a typical feature, except in those due to mutations in 
the KLHL genes. 
Recessive mutations in NEB and (de novo) dominant mutations in ACTA1 are the most 
common causes of NM. The pattern of selective muscle involvement in NEB-related NM 
(Table 2) has been reported in one small series [50] and is characterized in mild cases by 
complete sparing of the thigh muscles and selective involvement of the tibialis anterior and 
soleus (Case 3 and 4). In moderate cases, there may be predominant involvement of rectus 
femoris, vastus lateralis and hamstring muscles and diffuse involvement of anterior 
compartment and soleus. Muscle imaging in ACTA1-related myopathies has been reported in 
isolated cases and families with variable clinico-pathological and radiological features [50-
52]. Whole body MRI performed in one family with a TPM2-related myopathy suggested 
prominent rectus femoris, vastus lateralis and semimembranosus involvement in the thigh, 
and prominent soleus involvement in the leg [53].     
  
Congenital muscular dystrophies 
The congenital muscular dystrophies (CMDs) are a genetically heterogeneous group of 
conditions characterized by variable but often profound weakness, moderate to marked CK 
elevations and dystrophic features on muscle biopsy (for review, [54]). In contrast to the 
congenital myopathies, immunohistochemical studies demonstrating the reduction or absence 
of specific proteins are diagnostically more important than structural abnormalities on muscle 
biopsy. CMDs are most commonly caused by mutations in genes encoding for basal lamina 
and extracellular matrix components, in particular recessive mutations in the LAMA gene 
encoding laminin α2, genes involved in glycosylation of α-dystroglycan (the 
“dystroglycanopathies”), and the COL6 and LMNA genes. Because of the profound weakness, 
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muscles are often too diffusely involved to still exhibit a diagnostically relevant pattern, or 
may exhibit a “negative pattern” with the very few muscles spared providing a diagnostic 
clue. As there is often associated CNS involvement, brain imaging is at least as diagnostically 
relevant as muscle imaging, and may reveal characteristic abnormalities such as the typical 
white matter changes in LAMA-associated CMD, or a wide range of structural brain 
abnormalities in the dystroglycanopathies.       
Muscle imaging has been most widely performed in forms of CMD due to recessive and 
dominant mutations in one of the 3 COL6 genes [22, 55-57], a group of conditions where it 
may also be diagnostically most helpful, considering the often significant clinico-pathological 
overlap with the structural congenital myopathies (see above).  At the more severe end of the 
spectrum, typically recessively inherited Ullrich congenital muscular dystrophy (UCMD) is 
characterized by usually marked weakness, proximal joint contractures in the context of distal 
laxity, and early respiratory impairment. Patients with the allelic and typically dominantly 
inherited Bethlem myopathy (BM) are usually more mildly affected, with a different 
contractural pattern and less severe respiratory impairment. In addition to variable myopathic 
or dystrophic changes on muscle biopsy, UCMD may show diagnostic reduction of collagen 
VI but this can be subtle or even normal; particularly in the latter cases muscle imaging may 
provide additional clues. Although some relative sparing (for example, of the rectus femoris, 
sartorius and gracilis within the thigh) (Table 2) has been reported, in the COL6-related 
myopathies the internal appearance of muscle on MRI (in particular hyperintense alternating 
normo- or hypointense areas) is diagnostically more important than the overall pattern of 
selectivity: This appearance has been described in many different ways (“tigroid” pattern, 
“rolled-cake” appearance), but essentially reflects a regularly structured co-existence of 
normal and abnormal tissue within the same muscle (Figure 3I). A similar pattern may be 
observed in isolated muscles in other neuromuscular disorders, for example DYSF and 
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CAPN3-related LGMD (see below), but is usually not as extensive as in the collagenopathies 
where a wide range of muscles – rectus femoris, vastus, soleus, gastrocnemius, triceps, 
deltoid – may be affected.  
Muscle imaging in the other CMDs has been performed in milder forms of CMD due to 
LAMA mutations, demonstrating prominent posterior and medial involvement (mainly 
concerning the adductor magnus) within the thigh, and soleus muscle involvement in the 
lower legs. The pattern in milder cases of LMNA-related CMD shows a continuum with other 
laminopathies, particular in the lower limbs (see below), whereas in more severe cases, whole 
body MRI may be required to demonstrate residual sparing of forearm, psoas, masticator and 
tongue muscles as a diagnostic clue [22]. Although not specific, marked lipodystrophy is 
another diagnostic feature in laminopathies. The only form of dystroglycanopathy where 
muscle imaging has been more widely performed are those due mutations in the FKRP gene 
with considerable overlap with the LGMD2I spectrum (see below).  
 
Dystrophinopathies 
Although less relevant from a diagnostic perspective, there is a rapidly increasing body of 
literature concerning muscle MR imaging in Duchenne muscular dystrophy [58-68], Becker 
muscular dystrophy [69-72], and carriers of these conditions [73], with the main aim to 
delineate the timely and spatial pattern of selective muscle involvement more accurately and 
to quantify intramuscular fatty changes more reproducibly as a biomarker [60, 71].  The 
pattern of selective muscle involvement identified through these studies (Table 2) shows both 
variability and consistency in boys with DMD: Within the thigh, adductor magnus is involved 
early followed by vasti, rectus and biceps femoris, whereas other hamstring muscles become 
affected later and gracilis, adductor longus and (less frequently) sartorius may remain spared 
well into the disease course [58, 63]. Within the lower leg, soleus [64, 65] and gastrocnemius 
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[65] are the earliest muscles to be involved followed by the peroneal group.  The pattern in 
BMD [69, 70] and manifesting DMD carriers [73] is similar but less severe and less 
progressive. Muscle MR imaging findings have been correlated with histological features 
[65], function and strength in DMD [66-68], and have also been used in the 
dystrophinopathies to assess the effects of exercise [62] and steroid treatment [59]. With an 
increasing number of therapies targeting the dystrophinopathies currently being developed, it 
is likely that in particular novel muscle imaging techniques will become increasingly relevant 
for natural history studies and to assess the effects of therapeutic interventions.  
 
Emerinopathies and laminopathies 
Emery-Dreifuss muscular dystrophy (EDMD) has been attributed to X-linked recessive 
mutations in the Emerin (EDMD) (EDMD1) and autosomal-dominant mutations in the LMNA 
gene (EDMD2) and is characterized by marked spinal rigidity, a scapuloperoneal distribution 
of weakness and often severe cardiac involvement. CK may be normal or mildly to 
moderately elevated. Muscle biopsy findings are variable, ranging from mild myopathic 
changes to complete fatty replacement of muscle; additional inflammatory changes may be 
prominent. Muscle imaging studies have been performed more frequently in the autosomal-
dominant than the rarer X-linked recessive form [22, 74-76], and may help to distinguish 
these conditions from other genetic forms of the RSS (see above) [76, 77]. The typical pattern 
in LMNA-associated EDMD (Table 2) is characterized by prominent involvement of the 
lower leg, with marked affectation of the soleus and the gastrocnemius medialis compared to 
the gastrocnemius lateralis muscle [74]. In the less involved thigh, the adductors, vasti, 
semimembranosus and the long head of the biceps femoris are typically affected. Studies 
comparing the X-linked recessive and the autosomal-dominant forms directly suggest that the 
typical lower leg involvement may be present earlier in EDMD2 [74], whereas at a later stage 
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EDMD1 may show a degree of peroneal involvement not present in EDMD2 [75]. A similar 
pattern varying in severity is seen in the wide group of other LMNA-related disorders (the 
“laminopathies” [78]), including bona fide neuromuscular phenotypes such as LGMD1B but 
also multisystemic manifestations including familial partial lipodystrophies and 
predominantly cardiac phenotypes [79, 80].       
 
Limb girdle muscular dystrophies 
The limb girdle muscular dystrophies (LGMDs) (for review, [81]) are a genetically 
heterogeneous group of conditions associated with both recessive and dominant inheritance, 
characterized clinically by proximal weakness often pronounced in the hip girdle, sparing of 
facial and extraocular muscles, and variable cardiorespiratory involvement. 
In addition to non-specific dystrophic features on muscle biopsy, inflammatory changes may 
be prominent, occasionally giving rise to diagnostic confusion. Specific 
immunohistochemical studies may help in delineating specific genetic forms but are not 
always unequivocally diagnostic; muscle imaging may provide additional useful information 
in such cases. In the group of recessive LGMDs (designated as LGMD2 with alphabetic 
lettering representing the specific genetic background), the most common forms (in order of 
ascending age of presentation) are LGMD2C-F due to mutations in the sarcoglycan genes, 
LGMD2A due to mutations in the calpain 3 (CAPN3) gene, LGMD2I due to mutations in the 
FKRP gene, LGMD2B due to mutations in the dysferlin (DYS) gene, and LGMD2L due to 
mutations in the more recently discovered anoctamin 5 (ANO5) gene. Muscle imaging studies 
in the sarcoglycanopathies are rare, but in contrast to LGMD2A, LGMD2B and LGMD2I 
where posterior compartment involvement is prominent, show more pronounced anterior 
compartment involvement [5] similar to the pattern observed in the dystrophinopathies (see 
above) .         
Muscle imaging and myopathology 
18 
 
Selective muscle involvement in LGMD2A has been documented in several series [82-84] 
and may provide useful supportive diagnostic information in the 20% of patients where 
calpain 3 expression on Western blot is normal.  Corresponding to clinical findings, there is 
marked posterior compartment involvement in the pelvis (in particular gluteus maximus), 
within the thigh (in particular biceps femoris, semimembranosus and adductor muscles) and 
in the lower leg (soleus and gastrocnemius medialis) (Table 2, Figure 3B). The pattern in 
LGMD2I (Table 2) [82, 85] is similar with comparable posterior compartment emphasis, but 
may show more prominent involvement of the vastus lateralis, less selective involvement in 
the posterior calf muscles and more pronounced sparing of the often hypertrophic tibialis 
posterior [82]. The Dixon technique has been used to quantify fat more accurately as an 
outcome measure in LGMD2I [85]. The pattern in LGMD2B [82, 84, 86-88] is probably 
more variable compared to LGMD2A and LGMD2I, with more variable anterior and 
posterior involvement in different patients [82]. A recent comprehensive study of 27 patients 
investigated by whole body MRI at different ages [87] suggests early and severe involvement 
of the hamstring muscles and the adductors in the thigh, and of the soleus and gastrocnemius 
muscle in the leg. Of note, clinically distinct dysferlinopathies – LGMD2B, Miyoshi 
muscular dystrophy (MMD1) and distal myopathy with anterior tibial onset – often share the 
same pattern of selective involvement on muscle imaging [88]. The more recently described 
LGMD2L secondary to recessive mutations in the ANO5 gene shows some clinical overlap 
with the dysferlinopathies, in particular if the presentation is more distal, but is distinguished 
by later onset, and cardiac involvement in some patients. The pattern on muscle MRI [89] 
(Table 2) with early posterior compartment involvement (Figure 3E) shows considerable 
overlap with other recessively inherited forms of LGMD, and despite the suggestion of minor 
distinguishing features in some series [90, 91], may not be particularly helpful to inform the 
differential diagnosis. As in other LGMDs, inflammatory changes may precede the 
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emergence of fatty muscle infiltration [92]. Muscle MRI may also useful to distinguish late-
onset acid maltase deficiency, occasionally presenting as a phenocopy of recessive LGMDs 
but showing unusually severe and early adductor involvement (Figure 3D) [93]. 
Dominantly inherited LGMDs (designated as LGMD1 with alphabetic lettering representing 
the specific genetic background) account for only 10% of all forms of all LGMDs and show 
considerable overlap with other dominantly inherited disorders. LGMD1A due to dominant 
mutations in MYOT encoding myotilin is allelic to a form of myofibrillar myopathy (MFM) 
(see below). LGMD1B due to dominant mutations in lamin A/C (LMNA) is part of the 
spectrum of the laminopathies, and the muscle MRI pattern in these conditions [22, 75, 76, 
79, 80] has been discussed above. LGMD1C due to dominant mutations in the CAV3 gene 
encoding caveolin 3 is part of a spectrum of disorders (the “caveolinopathies”), comprising 
LGMD, rippling muscle disease (RMD), asymptomatic hyperCKaemia and a distal 
myopathy. There are only few anecdotal reports describing muscle imaging studies in these 
conditions, suggesting a posterior and medial pattern in the thigh, with early involvement of 
the rectus femoris that is unusual in the context of other LGMDs, or most neuromuscular 
disorders in general [94, 95].   
 
Fascioscapulohumeral muscular dystrophy (FSHD) 
Fascioscapulohumeral muscular dystrophy (FSHD) is the third most common muscular 
dystrophy and in more than 95% of cases caused by a contracted D4Z4 macrosatellite array 
on the subtelomeric region of chromosome 4q. The condition usually presents from 
adolescence with facial, shoulder, abdominal and limb girdle weakness but atypical 
presentations are recognized.  
FSHD has been extensively studied by muscle imaging (including a number of whole body 
MRI studies) [96-108], mainly with the aim to accurately delineate the pattern and quality of 
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muscle involvement with a view to natural history studies and as an outcome measure for 
therapeutic interventions. The trapezius, serratus anterior and teres major are the earliest and 
most severely affected muscles, followed by pectoralis and latissimus dorsi, with consistent 
sparing of the spinati and subscapularis muscles [97, 107]. In the lower limb (Table 2), there 
is early and severe involvement of the hamstring muscles and the adductors within the thigh, 
and of the soleus, gastrocnemius medialis and tibialis anterior in the lower leg. The 
combination of tibialis anterior involvement and lack of rectus femoris sparing is unusual in 
the context of other neuromuscular disorders and may provide a diagnostic clue. Although 
there is often asymmetrical involvement [97, 98, 106] this may not be as pronounced as 
expected on clinical grounds. Muscle edema may be an early feature [96]. The combination 
of marked axial muscle involvement and a suggestive pattern of involvement in the shoulder 
girdle and limbs may present a diagnostic clue in patients presenting with isolated 
camptocormia rather than more typical features [101, 106]. Additional studies have correlated 
muscle MR imaging findings and muscle function and strength in patients with FSHD [98, 
109].  As with other common muscular dystrophies, there are ongoing efforts to quantify fat 
infiltration as a biomarker for natural history studies and therapeutic interventions [100, 103]   
 
Myotonic dystrophies 
Myotonic dystrophy is due to a dominantly inherited unstable triplet repeat expansion in the 
DMPK gene encoding dystrophia myotonic-protein kinase (DM1), or, less frequently, an 
unstable intronic CCTG expansion in the CNBP/ZNF9 gene (DM2). DM1 is the most 
common adult muscular dystrophy and characterized by muscle weakness and wasting, 
myotonia, and multisystem involvement variably affecting the brain, heart, lens and the 
endocrine system.  
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DM1 has been extensively studied by muscle imaging [84, 110-117]. Although myotonic 
dystrophy is usually a clinical diagnosis, patients presenting with mild or atypical features 
may enter the differential diagnosis of other neuromuscular disorders, and knowledge of the 
pattern of selective involvement on muscle imaging is therefore useful: In DM1, there is 
prominent anterior compartment involvement in the thigh and prominent posterior 
compartment involvement in the lower leg. There is a typical “semilunar” appearance within 
the vasti, reflective of perifemoral degeneration, and additional semitendinosus and 
semimembranosus involvement. In the lower leg, there is prominent soleus and 
gastrocnemius medialis involvement, but the tibialis anterior is also often affected. Changes 
in the tibialis anterior have also been specifically investigated with a view to their potential as 
a biomarker in DM1 [116-118]. In one comparative study the pattern of selective 
involvement in DM2 was considered similar, with the exception of more marked involvement 
of the erector spinae muscles [112, 119].   
 
Myofibrillar myopathies 
The myofibrillar myopathies (MFMs) (for review, [120]) are a group of genetically 
heterogeneous, late-onset disorders with often prominent distal weakness and variable 
multisystem involvement. The histopathological hallmarks are areas of focal myofibrillar 
disruption, desmin-positive inclusions on immunohistochemistry and ultrastructural 
abnormalities on electron microscopy. MFMs have been attributed to mutations in DES 
encoding desmin, CRYAB encoding αB-crystallin, MYOT encoding myotilin, FLNC encoding 
filamin C, BAG3 encoding Bcl-2-associated athonogene 3, ZASP encoding Z-band 
alternatively spliced PDZ-containing protein and other genetic backgrounds [120]. There is 
likely to be further genetic heterogeneity as around half of all patients with MFMs remain 
currently genetically unresolved. MFMs have to be distinguished from other neuromuscular 
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disorders and from each other, and as often neither clinical nor pathological features are 
entirely specific, muscle imaging may be very useful to inform the differential diagnosis.   A 
large muscle imaging series of 46 patients with different MFMs (mainly related to mutations 
in DES and MYOT) [121] suggests that there are two distinct pattern of muscle involvement, 
one common to DES- and CRYAB-related forms and the other shared between MYOT-, 
FLNC- and ZASP-related forms. DES-related MFM is characterized within the thigh by early 
semitendinosus, sartorius and gracilis involvement, the latter finding very unusual in other 
neuromuscular disorders (Table 2, Figure 3F). In the lower leg, there is prominent early 
peroneus involvement. The pattern in MYOT-related MFM represents almost a mirror image, 
with prominent involvement of the semimembranosus, biceps femoris and adductor magnus 
compared to the semitendinosus, and relative sparing of the gracilis and sartorius (Table 2, 
Figure 3G). In the lower leg, there is prominent involvement of the soleus, gastrocnemius 
medialis and also the tibialis anterior. A more recent whole body MRI studiy comparing 
DES- and MYOT-related MFM confirms above features and provides additional information 
regarding upper limb involvement [122, 123].   
 
CONCLUSIONS AND OUTLOOK 
 
Over the last two decades muscle imaging has become an established modality both for the 
diagnosis and monitoring of neuromuscular disorders. In future, the increasing use of whole 
body MRI protocols will further increase the diagnostic yield, in particular if combined with 
computational meta-analytical approaches that are likely to replace the currently prevailing 
and often subjective interpretation of lower limb muscle MRIs; these new techniques of 
automatic graphical representation are increasingly used in a diagnostic setting and have 
already provided the basis for some of the studies cited in the present review. Recent rapid 
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genetic advances will result in genetic testing performed increasingly early in the diagnostic 
process, however, muscle imaging is likely to retain its role, probably with a stronger 
emphasis on aiding genetic variant interpretation rather than informing the primary choice of 
gene(s) to be analysed. Whilst common neuromuscular disorders have been studied in larger 
series providing reliable information regarding the typical selective involvement, in particular 
novel and rare genetic neuromuscular disorders will require substantial collaborative 
multicentre efforts to establish diagnostic patterns. There is also a need for comparative 
studies, correlating for example muscle MRI with muscle US findings as a method that can 
be applied more readily and at less cost at the bedside. Lastly, novel quantitative muscle 
imaging techniques allowing reliable and reproducible muscle fat fraction assessments will 
result in the increasing use of muscle MR imaging in natural history studies and as an 
outcome measure in clinical trials. 
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FIGURE AND TABLE LEGENDS 
 
FIGURE LEGENDS 
 
Figure 1 Correlation between histopathological and muscle MRI features. Muscle 
biopsies from the vastus lateralis (VL) (A) and the rectus femoris (RF) (C), hematoxylin & 
eosin (H&E) stains, transverse sections from a Paediatric patient with a recessive RYR1-
related myopathy. Muscle magnetic resonance imaging (MRI) from the same patient, 
transverse section from the proximal thigh, T1-weighted images (B). Muscle biopsy from the 
vastus lateralis shows marked increases in fat and connective tissue, reflected in increased 
signal within the same muscle on T1-weighted MRI from the thigh. Muscle biopsy from the 
rectus femoris shows increased fibre size variability but less increase in connective tissue and 
fat compared to the vastus lateralis, reflected in relative sparing of the same muscle on T1-
weighted MRI from the thigh. 
 
Figure 2 Normal muscle anatomy in the lower limb. Schematic representation of normal 
muscle anatomy and T1-weighted muscle MR images from a normal individual, mid-thigh 
(A) and mid-calf (B) level.  VL = vastus lateralis, VI = vastus intermedius, RF = rectus 
femoris, VM = vastus medialis, S = sartorius, G = gracilis, AM = adductor magnus, Sm = 
semimembranosus, St = semitendinosus, BL = biceps femoris, long head, AT = tibialis 
anterior, EDL = extensor digitorum longus, PG = peroneal group, Gl = gastrocnemius 
lateralis, Gm = gastrocnemius medialis, So = Soleus, TP = tibialis posterior.   
 
Figure 3 Patterns of selective involvement in different genetic neuromuscular disorders. 
T1-weighted images, transverse sections at the mid-thigh and mid-calf level from patients 
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with (A) TTN-related myopathy, (B) CAPN3-related LGMD2A, (C) RYR1-related congenital 
myopathy, (D) acid maltase deficiency, (E) ANO5-related LGMD2L, myofibrillar 
myopathies due to mutations in the (F) DES and (G) MYOT genes, (H) rigid spine syndrome 
(RSS) secondary to recessive SEPN1 mutations,  and (I) Bethlem myopathy secondary to 
dominant mutations in the COL6 gene. For more detailed descriptions see main text. Figure 
courtesy of Professor Volker Straub, Newcastle, United Kingdom. 
 
Figure 4 Muscle imaging and histopathological features from illustrative case studies. 
T1-weighted muscle MR images from the thigh, (A) from a patient with a dominantly 
inherited and (B) Case 1 with a recessively inherited RYR1-related myopathy. The (C) muscle 
biopsy from Case 1 (NADH-TR, transverse section) showed only non-specific features, and 
RYR1 testing was only performed because of the evocative muscle MRI pattern. (D) T1-
weighted muscle MR images from the thigh from Case 2 with a recessively inherited MYH2-
related myopathy. Despite a similar (E) muscle biopsy appearance with marked type 1 
predominance and some unevenness of stain, the muscle MRI did not support RYR1 
involvement.  T1-weighted muscle MR images from the lower leg in two sisters (older sister 
Case 3 (F), younger sister Case 4 (G)) with an unresolved congenital myopathy. The family 
refused a diagnostic muscle biopsy but, in the given clinical context, NEB-related nemaline 
myopathy was strongly suggested by marked tibialis anterior and soleus involvement, and 
was subsequently confirmed on specific genetic testing. Note intrafamilial consistency with 
almost identical muscle MRI findings in the two sisters.  
 
Figure 5 Whole body MRI from a 16-year-old female with a RYR1-weighted myopathy 
and predominant proximal weakness. 
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Selection of axial T1-weighted images from the head/face (A-D), shoulder girdle, arms and 
trunk (E-I), pelvis (J), thighs (K-N), legs (O-Q) and feet (R). In the face, the temporal 
muscles (A, *) and masseter (C, ++) are atrophic whereas lateral and medial pterygoïd 
muscles are relatively better preserved. Muscles of the scapular girdle (E) are all atrophic and 
largely replaced by fat; the most affected muscles are the pectoralis major (white arrow) and 
the subscapularis (double short white arrowheads). The biceps brachialis (F) as well as the 
lumbar erector (H, I) and psoas/iliac (I-K, sinuous arrow) muscles are slightly atrophic and 
infiltrated with fat. In the thighs (L-N), there is diffuse involvement with relative sparing of 
the rectus femoris, sartorius, gracilis and adductor longus. In the lower legs and feet (O-R), 
there is diffuse involvement of the anterior compartment, soleus and medial gastrocnemius 
proximally, with the peroneal group more prominently involved distally. Figure courtesy of 
Professor Robert Carlier, Paris, France. 
 
TABLE LEGENDS 
 
Table 1 Correlation of histopathological abnormalities on muscle biopsy and muscle 
magnetic resonance imaging findings. SI = signal intensity; T1W = T1-weighted image; 
T2W = T2-weighted image; STIR = short tau inversion recovery 
 
Table 2 Muscle involvement in selected inherited neuromuscular disorders.  
Reported patterns of selective muscle involvement in the congenital myopathies (CM), 
congenital muscular dystrophies (CMD), Duchenne muscular dystrophy (DMD), Emery-
Dreifuss muscular dystrophy (EDMD), limb girdle muscular dystrophies (LGMD), 
fascioscapulohumeral dystrophy (FSHD), myotonic dystrophy (DM1) and myofibrillar 
myopathies (MFM). Black boxes indicate muscle groups that are involved early and/or 
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severely in the disease course, empty boxes indicate muscle groups that are consistently 
spared until late into the disease course, and shaded boxes indicate muscle groups that are 
involved later in the disease course or where there is variable involvement.   VL = vastus 
lateralis, VI = vastus intermedius, RF = rectus femoris, VM = vastus medialis, Sa = sartorius, 
Gr = gracilis, AM = adductor magnus, Sm = semimembranosus, St = semitendinosus, BL = 
biceps femoris, long head, AT = tibialis anterior, EDL = extensor digitorum longus, PG = 
peroneal group, TP = tibialis posterior Gl = gastrocnemius lateralis, Gm = gastrocnemius 
medialis, So = Soleus. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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SUPPLEMENTAL INFORMATION - CASE STUDIES 
 
CASE 1 – Muscle MRI informing the choice of genetic testing 
 
This 19-year-old lady (reported in [21]) presented with signs and symptoms of proximal 
weakness and a non-progressive mild scoliosis from the age of 4 years. She was the only 
child of a consanguineous Caucasian couple and there was no preceding family history of 
neuromuscular disorders or adverse reactions to general anaesthesia. Perinatal history and 
early developmental milestones had been normal.  
On examination there was mild facial weakness but no ptosis and no extraocular muscle 
involvement. She had mild to moderate axial and proximal weakness pronounced in the hip 
girdle with an exaggerated lumbar lordosis. There was a mild scoliosis and bilateral Achilles 
tendon tightness but no other contractures.    
Her further course remained stable. She remained fully ambulant but occasionally complaint 
about exertional myalgia. There were no bulbar or respiratory symptoms. Investigations 
included a normal CK at 151 IU/l. She had 3 muscle biopsies which were all considered 
myopathic but without suggesting a specific diagnosis. The most recent muscle biopsy 
(Figure 4C) performed at 15 years of age showed increased variability in fibre size and an 
increase in internalized nuclei, marked type 1 predominance and a few cores although those 
were not prominent. Muscle MRI (Figure 4B) demonstrated increased signal intensity within 
the adductor magnus, vasti and sartorius, with relative sparing of the rectus femoris, gracilis 
and hamstring muscles. Because of the striking similarities between the muscle MRI scan 
from the patient and the MRI scan from a patient with an already genetically resolved RYR1-
related myopathy (Figure 4A), Sanger sequencing of RYR1 mutational hotspots was initiated; 
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this revealed homozygosity for a C-terminal RYR1 missense mutation (c.14545G>A; 
p.Val4849Ile), confirming the diagnosis of a recessive RYR1-related myopathy.  
 
CASE 2 – Muscle MRI aiding genetic variant interpretation 
 
This 14-year-old girl presented with mild motor developmental delay following an uneventful 
pregnancy. She was the 4th child of a consanguineous Asian couple and there was no 
preceding family history of neuromuscular disorders. She failed to thrive from early on in life 
despite adequate calorie intake in the absence of overt chewing or swallowing difficulties. 
On examination there was mild facial weakness and ptosis with almost complete 
opthalmoplegia. Weakness was moderate in axial muscles and in the shoulder girdle, and 
mild in the hip girdle.     
Her further course remained stable in functional terms but she continued to complain about 
easy fatiguability and myalgia. Ongoing failure to thrive required gastrostomy insertion 
resulting in improved weight gain.  
Investigations included a normal CK. A muscle biopsy (Figure 4E) performed early in life 
had shown increased variability in fibre size and marked type 1 predominance with some 
unevenness of stain. RYR1 sequencing prompted by the suspicion of a recessive RYR1-related 
myopathy revealed a heterozygous variant (c.5360C>G; p.Pro1787Leu) of uncertain 
significance but probably a polymorphism. Muscle MRI (Figure 4D) showed an almost 
normal appearance in the thigh and the lower leg, in contrast to most RYR1-related 
myopathies where at this stage at least some involvement of vasti and adductor magnus 
would be expected. Further testing through a congenital myopathy next generation 
sequencing panel revealed a homozygous mutation (MYH2) gene (c.2347C>T; p.Arg783Ter) 
in the myosin heavy chain 2 gene. She also carried a heterozygous mutation (c.1315C>T; 
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p.Arg439Ter) in the SEPN1 gene which was not considered causative considering that the 
heterozygous carrier parent was asymptomatic, in keeping with the consistently recessive 
inheritance of SEPN1-related myopathies. Moreover, muscle MRI did not even show subtle 
features suggestive of a SEPN1-related myopathy (i.e. early sartorius involvement).     
 
CASE 3 and 4 – Muscle MRI substituting for muscle biopsy  
 
These 14- and 12-year-old sisters presented from early childhood with easy fatiguability, a 
limited walking distance and difficulties running with frequent falls. Perinatal history and 
early developmental milestones were within normal limits. There was no history of bulbar or 
respiratory problems.  
On examination, there was moderate facial weakness with non-fatiguable ptosis but no 
extraocular muscle involvement. In both sisters, there was moderate axial and proximal 
weakness with additional distal involvement pronounced in ankle dorsiflexion. 
The further course remained stable in terms of functional abilities but both sisters developed a 
scoliosis and symptoms of nocturnal hypoventilation, requiring a thoracic brace and non-
invasive night-time ventilation, respectively. 
Investigations included a normal CK (161 IU/l) and normal EMG/NCS. The family were 
reluctant to consider a muscle biopsy because of its invasive nature. Muscle MRI showed an 
identical pattern in both sisters (Figure 4G and 4C), characterized by predominant 
involvement of the tibialis anterior, in the context of clinical features suggestive of NEB-
related nemaline myopathy. Subsequent genetic testing through a next generation sequencing 
congenital myopathy panel revealed a homozygous NEB mutation 
(c.24178_24181dupGTCA; p.Lys8061fs) cosegregating with the disease phenotype.   
 
